Acasti Pharma Inc. NASDAQ:ACST

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

Acasti Pharma stock price monthly change

-1.89%
month

Acasti Pharma stock price quarterly change

-8.23%
quarter

Acasti Pharma stock price yearly change

+447.37%
year

Acasti Pharma key metrics

Market Cap
34.17M
Enterprise value
N/A
P/E
-1.34
EV/Sales
N/A
EV/EBITDA
0.35
Price/Sales
N/A
Price/Book
0.21
PEG ratio
-0.01
EPS
-1.58
Revenue
N/A
EBITDA
-12.01M
Income
-13.29M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Acasti Pharma stock price history

Acasti Pharma stock forecast

Acasti Pharma financial statements

Acasti Pharma Inc. (NASDAQ:ACST): Profit margin
Jun 2023 0 -4.02M
Sep 2023 0 -3.71M
Dec 2023 0 -2.39M
Mar 2024 0 -3.16M
Acasti Pharma Inc. (NASDAQ:ACST): Analyst Estimates
Sep 2025 0 -3.68M
Oct 2025 0 -3.01M
Dec 2025 0 -3.63M
Mar 2026 0 -4.30M
  • Analysts Price target

  • Financials & Ratios estimates

Acasti Pharma Inc. (NASDAQ:ACST): Debt to assets
Jun 2023 73033000 9.02M 12.35%
Sep 2023 78210000 11.46M 14.66%
Dec 2023 76185000 11.50M 15.1%
Mar 2024 73300000 11.55M 15.77%
Acasti Pharma Inc. (NASDAQ:ACST): Cash Flow
Jun 2023 -6.24M 0 0
Sep 2023 -2.11M 110K 7.35M
Dec 2023 -1.89M -6.55M -65.33K
Mar 2024 -2.17M 6.49M 61.02K

Acasti Pharma alternative data

Acasti Pharma Inc. (NASDAQ:ACST): Employee count
Aug 2023 32
Sep 2023 32
Oct 2023 32
Nov 2023 32
Dec 2023 32
Jan 2024 32
Feb 2024 32
Mar 2024 32
Apr 2024 32
May 2024 32
Jun 2024 32
Jul 2024 32

Acasti Pharma other data

0.31% +0.19%
of ACST is owned by hedge funds
136.49K +86.16K
shares is hold by hedge funds

Acasti Pharma Inc. (NASDAQ:ACST): Insider trades (number of shares)
Period Buy Sel
Aug 2023 381 0
Sep 2023 1099103 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
KAVURU VIMAL director, 10 percent owner:
Common Shares 676,371 $1.85 $1,249,934
Purchase
KAVURU VIMAL director, 10 percent owner:
Common Warrants (right to buy) 422,732 $3 $1,269,464
Purchase
OLDS DONALD director
Common Shares 381 $2.05 $781
Patent
Application
Filling date: 7 Feb 2020 Issue date: 28 Apr 2022
Application
Filling date: 9 May 2019 Issue date: 5 Aug 2021
Application
Filling date: 15 May 2019 Issue date: 18 Mar 2021
Insider Compensation
Ms. Janelle D'Alvise (1955) Pres, Chief Executive Officer, Corporation Sec. & Director
$428,040
Mr. Brian D. Ford CPA, CA (1959) Chief Financial Officer
$364,820
Dr. Pierre Lemieux M.D., Ph.D. (1965) Co-Founder, Chief Operating Officer & Chief Scientific Officer
$276,380
Friday, 25 October 2024
globenewswire.com
Wednesday, 25 September 2024
globenewswire.com
Thursday, 5 September 2024
globenewswire.com
Friday, 9 August 2024
globenewswire.com
Wednesday, 10 July 2024
zacks.com
Thursday, 27 June 2024
globenewswire.com
Friday, 21 June 2024
globenewswire.com
Tuesday, 18 June 2024
investorplace.com
Tuesday, 28 May 2024
globenewswire.com
Thursday, 23 May 2024
investorplace.com
Monday, 12 February 2024
globenewswire.com
Wednesday, 13 December 2023
GlobeNewsWire
Wednesday, 6 September 2023
GlobeNewsWire
Wednesday, 9 August 2023
GlobeNewsWire
Tuesday, 28 February 2023
Zacks Investment Research
Tuesday, 14 February 2023
Seeking Alpha
Tuesday, 24 January 2023
GlobeNewsWire
Friday, 13 January 2023
GlobeNewsWire
Thursday, 5 January 2023
GlobeNewsWire
Wednesday, 28 December 2022
PennyStocks
Monday, 14 November 2022
Seeking Alpha
Wednesday, 9 November 2022
GlobeNewsWire
Monday, 7 November 2022
GlobeNewsWire
Wednesday, 14 September 2022
GlobeNewsWire
Monday, 12 September 2022
GlobeNewsWire
Tuesday, 2 August 2022
GlobeNewsWire
Thursday, 16 June 2022
GlobeNewsWire
Wednesday, 18 May 2022
Benzinga
PennyStocks
Monday, 25 April 2022
GlobeNewsWire
  • When is Acasti Pharma's next earnings date?

    Unfortunately, Acasti Pharma's (ACST) next earnings date is currently unknown.

  • Does Acasti Pharma pay dividends?

    No, Acasti Pharma does not pay dividends.

  • How much money does Acasti Pharma make?

    Acasti Pharma has a market capitalization of 34.17M.

  • What is Acasti Pharma's stock symbol?

    Acasti Pharma Inc. is traded on the NASDAQ under the ticker symbol "ACST".

  • What is Acasti Pharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Acasti Pharma?

    Shares of Acasti Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Acasti Pharma's key executives?

    Acasti Pharma's management team includes the following people:

    • Ms. Janelle D'Alvise Pres, Chief Executive Officer, Corporation Sec. & Director(age: 70, pay: $428,040)
    • Mr. Brian D. Ford CPA, CA Chief Financial Officer(age: 66, pay: $364,820)
    • Dr. Pierre Lemieux M.D., Ph.D. Co-Founder, Chief Operating Officer & Chief Scientific Officer(age: 60, pay: $276,380)
  • Is Acasti Pharma founder-led company?

    Yes, Acasti Pharma is a company led by its founder Dr. Pierre Lemieux M.D., Ph.D..

  • How many employees does Acasti Pharma have?

    As Jul 2024, Acasti Pharma employs 32 workers.

  • When Acasti Pharma went public?

    Acasti Pharma Inc. is publicly traded company for more then 13 years since IPO on 7 Feb 2012.

  • What is Acasti Pharma's official website?

    The official website for Acasti Pharma is acastipharma.com.

  • Where are Acasti Pharma's headquarters?

    Acasti Pharma is headquartered at 3009 boulevard de la Concorde East, Laval, QC.

  • How can i contact Acasti Pharma?

    Acasti Pharma's mailing address is 3009 boulevard de la Concorde East, Laval, QC and company can be reached via phone at +45 06872262.

Acasti Pharma company profile:

Acasti Pharma Inc.

acastipharma.com
Exchange:

NASDAQ

Full time employees:

32

Industry:

Biotechnology

Sector:

Healthcare

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

3009 boulevard de la Concorde East
Laval, QC H7E 2B5

CIK: 0001444192
ISIN: CA00430K8656
CUSIP: 00430K402